A Validated Composite Comorbidity Index Predicts Outcomes of CAR T Cell Therapy in Patients with Diffuse Large B Cell Lymphoma

Results indicated that adverse outcomes for patients with diffuse large B-cell lymphoma meant to receive CART could be predicted using a simplified cumulative illness rating scale-derived comorbidity index.